Lilly plans €330m biomanufacturing plant in Ireland
pharmafile | February 28, 2012 | News story | Manufacturing and Production | Abbott, Ireland, Kinsale, lilly
There was more good news for Ireland’s pharmaceutical sector this week with the announcement by Eli Lilly that it will invest €330 million in a new plant in Kinsale, County Cork, that will employ upwards of 200 people.
The 240,000 sq. ft plant, will “expand the Kinsale site’s existing biopharmaceutical mission with the establishment of an additional world-class commercialisation and manufacturing facility,” according to inward investment agency IDA Ireland.
A further 300 construction jobs will be created on the site during building works, said the firm.
Lilly has already invested €300 million on a biopharmaceutical production facility at Kinsale which came online in 2010 and employs 140 people. The plant is still completing its start-up and validation phase and is due to start manufacturing commercial product in late 2013.
The new facility – due to open in 2016 – will expand Kinsale’s ability to make new cancer and diabetes treatments, said the firm.
All told Lilly employs 400 people at the Kinsale site, which also has chemical manufacturing plants making active pharmaceutical ingredients for products such as antipsychotic Zyprexa (olanzapine), Evista (raloxifene) for osetoporosis, Strattera (atomoxetine) for attention deficit hyperactivity disorder and cancer drug Alimta (pemetrexed dosdium).
Paul Ahern, Lilly’s senior vice president for global API and dry product manufacturing said: “This investment is part of Lilly’s planned growth strategy and proof of our confidence in Lilly’s pipeline of new products, many of which are derived from biotechnology.”
Lilly’s announcement comes shortly after Abbott Laboratories said it would invest €85 million at its manufacturing plant in Sligo, Ireland, more than doubling staff there with the creation of 175 new pharmaceutical jobs.
Phil Taylor
Related Content
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …
Astellas plans to invest over €330m in new facility in Ireland
Astellas Pharma has announced that it is preparing to submit a planning application to build …
Abbott to acquire Bigfoot Biomedical
Abbott and Bigfoot Biomedical have announced a definitive agreement for Abbott to acquire Bigfoot, however …
